Response rates to pembrolizumab monotherapy by stage and presence of bulky disease
| Response . | All patients (n = 30) . | Advanced stage (n = 18) . | Early unfavorable (n = 12) . | Bulky (n = 12)* . | ||||
|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | |
| CMR (n = 30) | 11/30 | 37 | 6/18 | 33 | 5/12 | 42 | 3/12 | 25 |
| >90% but < 100% reduction in MTV | 7/28† | 25† | 4/18 | 22 | 3/10† | 30† | 5/10† | 50† |
| CMR or >90% but <100% reduction in MTV | 18/30 | 60 | 10/18 | 56 | 8/12 | 67 | 8/12 | 67 |
| Response . | All patients (n = 30) . | Advanced stage (n = 18) . | Early unfavorable (n = 12) . | Bulky (n = 12)* . | ||||
|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | |
| CMR (n = 30) | 11/30 | 37 | 6/18 | 33 | 5/12 | 42 | 3/12 | 25 |
| >90% but < 100% reduction in MTV | 7/28† | 25† | 4/18 | 22 | 3/10† | 30† | 5/10† | 50† |
| CMR or >90% but <100% reduction in MTV | 18/30 | 60 | 10/18 | 56 | 8/12 | 67 | 8/12 | 67 |
Any mass >10 cm in any dimension or a maximum mediastinal ratio >1:3.
Quantifiable cases; MTV could not be measured in 2 cases of bulky disease. In 1 case, areas of disease could not be distinguished from the PET-avid myocardium and in a second case, the computer program generated a 100% decline in MTV that was inconsistent with the qualitative assessment of Deauville 4.